Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04261049 · ClinicalTrials.gov registry record · Phase 1

Effect of Zilretta Injection

A Phase 1 study of Osteoarthritis, Knee, sponsored by University of North Carolina, Chapel Hill.

Completed
Registry status
Phase 1
Development phase
35
Enrollment target
1
Study location

NCT04261049 is a Phase 1 study of Osteoarthritis, Knee that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 35 participants, below the 580-participant average among 91 other Osteoarthritis, Knee trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04261049, a Phase 1 study of Osteoarthritis, Knee, has completed, sponsored by University of North Carolina, Chapel Hill.

COMPLETED
Registry status
Phase 1
Development phase
35 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to examine the pre-post effects of a single ZILRETTA knee injection on physiological measures of self-reported pain and disability, physical performance, and physical activity in individuals with knee osteoarthritis (OA). The investigators will recruit 35 symptomatic knee OA patients for this study. All data will be collected prior to injection (baseline), as well as at 4 (post 1) and 8-week follow-ups (post 2).

Conditions Studied

Interventions

  • DRUG Triamcinolone Acetonide Extended-Release Injectable Suspension

Study Locations (1)

North Carolina

  • MOTION Science Institute - Chapel Hill

Trial Details

FieldValue
Enrollment Target 35 participants
Start Date 2020-08-01
Est. Completion 2022-01-10
Phase Phase 1

What the Registry Record Tells You About NCT04261049

The ClinicalTrials.gov registry entry for NCT04261049 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 580-participant average among 91 other Osteoarthritis, Knee trials with a reported enrollment target (94% lower). The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Osteoarthritis, Knee appearing as the primary indexed condition, and to 1 intervention - of which Triamcinolone Acetonide Extended-Release Injectable Suspension is the first listed.

NCT04261049 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.

Frequently Asked Questions

What is clinical trial NCT04261049 about?

NCT04261049 is a clinical study titled "Effect of Zilretta Injection". The purpose of this study is to examine the pre-post effects of a single ZILRETTA knee injection on physiological measures of self-reported pain and disability, physical performance, and physical activity in individuals with knee osteoarthritis (OA). The investigators will recruit 35 symptomatic kne...

What is the current status of trial NCT04261049?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2020-08-01. Estimated completion is 2022-01-10.

What conditions does trial NCT04261049 study?

This clinical trial studies the following conditions: Osteoarthritis, Knee.

What interventions are being tested in trial NCT04261049?

The interventions under investigation include: Triamcinolone Acetonide Extended-Release Injectable Suspension (DRUG).

Who is sponsoring clinical trial NCT04261049?

This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04261049 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Osteoarthritis, Knee

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.